In the dynamic, often unpredictable world of investing, there are moments when market sentiment seems to detach from reality. This is one of those moments. Novo Nordisk, a Danish pharmaceutical company once primarily known for its insulin products, has now become a market darling—and perhaps, a dangerously overhyped one. The meteoric rise of its stock price has left many investors asking a serious question: Has the market lost its mind? In this post, we’ll take a deep dive into what’s really going on with Novo Nordisk—its business fundamentals, the source of the hype, the underlying risks, and whether investors are ignoring the signals of a classic bubble in the making. Section 1: The Meteoric Rise of Novo Nordisk Novo Nordisk’s stock has skyrocketed over the past few years. As of 2025, the company boasts a market cap that rivals that of Big Tech, surpassing many older pharmaceutical giants like Pfizer, Merck, and even Johnson & Johnson in certain metrics. Much of this rise ca...